The estimated Net Worth of Steven J. Romano is at least $4.62 Milion dollars as of 13 November 2017. Steven Romano owns over 2,000 units of Mallinckrodt Plc stock worth over $8,239 and over the last 9 years he sold MNK stock worth over $0. In addition, he makes $4,615,100 as Executive Vice President a Chief Scientific Officer at Mallinckrodt Plc.
Sign up
Steven Romano MNK stock SEC Form 4 insiders trading
Steven has made over 6 trades of the Mallinckrodt Plc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 2,000 units of MNK stock worth $43,920 on 13 November 2017.
The largest trade he's ever made was buying 2,000 units of Mallinckrodt Plc stock on 13 November 2017 worth over $43,920. On average, Steven trades about 330 units every 36 days since 2015. As of 13 November 2017 he still owns at least 24,232 units of Mallinckrodt Plc stock.
You can see the complete history of Steven Romano stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Steven Romano biography
Dr. Steven Romano M.D. is an Executive Vice President, Chief Scientific Officer of the Company. Dr. Romano joined Mallinckrodt in May 2015 and has executive responsibility for R&D, medical affairs and regulatory affairs functions. Dr. Romano is a board-certified psychiatrist with more than 20 years of experience in the pharmaceutical industry. Previously, Dr. Romano spent 16 years at Pfizer, Inc. where he held a series of senior medical and R&D roles of increasing responsibility, culminating with his role as Senior Vice President, Head of Global Medicines Development, Global Innovative Pharmaceuticals Business. Prior to joining Pfizer, he spent four years at Eli Lilly & Co. After receiving his A.B. in Biology from Washington University in St. Louis and his medical degree from the University of Missouri-Columbia, Dr. Romano completed his residency and fellowship at New York Hospital-Cornell Medical Center, continuing on the faculty of the medical school for an additional six years. Dr. Romano also serves as a director of Silence Therapeutics plc.
What is the salary of Steven Romano?
As the Executive Vice President a Chief Scientific Officer of Mallinckrodt Plc, the total compensation of Steven Romano at Mallinckrodt Plc is $4,615,100. There are 1 executives at Mallinckrodt Plc getting paid more, with Mark Trudeau having the highest compensation of $14,610,800.
How old is Steven Romano?
Steven Romano is 60, he's been the Executive Vice President a Chief Scientific Officer of Mallinckrodt Plc since 2016. There are 6 older and 7 younger executives at Mallinckrodt Plc. The oldest executive at Mallinckrodt Plc is J. Martin Carroll, 70, who is the Independent Director.
What's Steven Romano's mailing address?
Steven's mailing address filed with the SEC is McDonnell Boulevard, Hazelwood, Saint Louis County, Missouri, 63042, United States.
Insiders trading at Mallinckrodt Plc
Over the last 11 years, insiders at Mallinckrodt Plc have traded over $29,853,069 worth of Mallinckrodt Plc stock and bought 2,559,592 units worth $174,429,961 . The most active insiders traders include & Co. Inc. Paulson, James E Deerfield Mgmt L.P.... a Nancy Lurker. On average, Mallinckrodt Plc executives and independent directors trade stock every 29 days with the average trade being worth of $10,061. The most recent stock trade was executed by Jason Daniel Goodson on 16 March 2023, trading 1,133 units of MNK stock currently worth $9,495.
What does Mallinckrodt Plc do?
mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit
What does Mallinckrodt Plc's logo look like?
Complete history of Steven Romano stock trades at Mallinckrodt Plc
Mallinckrodt Plc executives and stock owners
Mallinckrodt Plc executives and other stock owners filed with the SEC include:
-
Mark Trudeau,
President, Chief Executive Officer, Director -
Steven Romano,
Executive Vice President, Chief Scientific Officer -
Hugh O'Neill,
Executive Vice President, Chief Commercial Officer -
Mark Casey,
Executive Vice President and Chief Legal Officer -
Bryan Reasons,
Chief Financial Officer, Executive Vice President -
Ian Watkins,
Chief Human Resource Officer, Executive Vice President -
Angus Russell,
Independent Non-Executive Chairman of the Board -
JoAnn Reed,
Independent Director -
J. Martin Carroll,
Independent Director -
David Norton,
Independent Director -
Kneeland Youngblood,
Independent Director -
Anne Whitaker,
Independent Director -
Paul Carter,
Independent Director -
Carlos Paya,
Independent Director -
Daniel Speciale,
Vice President - Investor Relations and IRO -
David R Carlucci,
Director -
Virgil D Thompson,
Director -
Diane H. Gulyas,
Director -
Matthew K Harbaugh,
SVP&Chief Financial Officer -
Michael Bryant Hicks,
Sr. VP & General Counsel -
Ronald K. Lloyd,
Sr. VP & Pres, Hospital -
Raymond J. Furey,
SVP & Chief Compliance Officer -
Gary M. Phillips,
Sr. VP & Chief Strategy Ofcr. -
Meredith B Fischer,
SVP, Communic. & Public Affair -
Melvin D Booth,
Director -
Joseph A Zaccagnino,
Director -
Coleman N Iii Lannum,
VP, Investor Relations -
Dagmar Rosa Bjorkeson,
Chief Strat & Corp Dev Officer -
Sigurdur O Olafsson,
President and CEO -
Kassie Harrold,
Chief Compliance Officer -
Jason Daniel Goodson,
EVP & Head of Corp Development -
Henriette Nielsen,
EVP & Chief Transformation OFC -
Lisa French,
EVP & Chief Commercial Officer -
Mark Anthony Tyndall,
EVP & Chief Legal Offi & Secre -
Stephen Andrew Welch,
EVP & Head of Spec Generics -
Frank Scholz,
SVP, Global Operations -
George A. Kegler,
EVP & CFO, Interim -
Karen Patruno Sheehy,
Sr. VP & Chief Compliance Off. -
James E Deerfield Mgmt L.P....,
-
Don M Bailey,
Director -
Sandra L Hatten,
Sr. Vice President Quality -
Terrance L Carlson,
Interim General Counsel -
& Co. Inc. Paulson,
10% owner -
Holding Ltd Enceladus,
-
Thomas E Berry,
See Remarks -
Peter G Edwards,
See Remarks -
Stefano R Carchedi,
See Remarks -
Stephen Merrick,
See Remarks -
Nancy Lurker,
Director -
Mario D. Saltarelli,
Sr. VP & Chief Science Ofcr. -
Kathy A Schaefer,
Sr. VP Fin & Corp. Controller -
Peter C Richardson,
EVP & Chief Scientific Officer -
Daniel Arthur Celentano,
Director -
Woodrow A Jr Myers,
Director -
Paul Bisaro,
Director -
James R Sulat,
Director -
Susan Michele Silbermann,
Director -
Karen Ling,
Director -
Neal P Goldman,
Director -
Riad Hussein El Dada,
Director